A retrovirus [lymphoadenopathy-associated virus, human T-cell leukemia virus type III, acquired immunodeficiency syndrome (AIDS)-related virus] suspected of causing AIDS has been isolated recently. The detection of exposure to this retrovirus in donors of various blood products is important to prevent transmission of the disease from these donors to recipients. In the majority of cases, the detection of antibodies directed against either the viral core protein, a Mr approximately equal to 24,000 protein termed p24 gag, or the viral envelope antigen is proof of previous viral infection. Thus, we have expressed the p24 gag antigen in Escherichia coli in order to produce a diagnostic reagent for the detection of virus exposure. The bacterially synthesized antigen reacts with human and rabbit antisera directed against the native p24 gag protein in both electrophoretic transfer blot assay and ELISA. In addition, the use of bacterially produced antigens for ELISAs gave results that were comparable to those obtained by using antigens isolated from the virus.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC391411 | PMC |
| http://dx.doi.org/10.1073/pnas.82.22.7748 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
IFI27 inhibits HIV-1 replication by degrading Gag protein through the ubiquitin-proteasome pathway.
J Virol
November 2024
State Key Laboratory of Genetic Evolution & Animal Models, Key Laboratory of Bioactive Peptides of Yunnan Province, KIZ-CUHK Joint Laboratory of Bioresources and Molecular Research in Common Diseases, Center for Biosafety Mega-Science, Kunming Institute of Zoology, Chinese Academy of Sciences, Kunming, Yunnan, China.
Article Synopsis
- Type I interferon (IFN-I) and its gene IFI27 are crucial in controlling HIV-1 infection by effectively suppressing viral replication and degrading its proteins, p24 and p55.
- The study found that the IFI27 variant from northern pig-tailed macaques (NPM-IFI27) is particularly effective against HIV-1, utilizing the ubiquitin-proteasome pathway to target and degrade viral proteins.
- These results highlight the potential of NPM-IFI27 as a promising candidate for new antiviral therapies against HIV-1, emphasizing the need for ongoing research in host antiviral agents.
Intra- and inter-subtype HIV diversity between 1994 and 2018 in southern Uganda: a longitudinal population-based study.
Virus Evol
August 2024
Department of Pathology, Johns Hopkins School of Medicine, 600 N. Wolfe Street, Baltimore, MD 21205, United States.
There is limited data on human immunodeficiency virus (HIV) evolutionary trends in African populations. We evaluated changes in HIV viral diversity and genetic divergence in southern Uganda over a 24-year period spanning the introduction and scale-up of HIV prevention and treatment programs using HIV sequence and survey data from the Rakai Community Cohort Study, an open longitudinal population-based HIV surveillance cohort. (p24) and (gp41) HIV data were generated from people living with HIV (PLHIV) in 31 inland semi-urban trading and agrarian communities (1994-2018) and four hyperendemic Lake Victoria fishing communities (2011-2018) under continuous surveillance.
View Article and Find Full Text PDFSustained antiviral response against HIV-1 infection in peripheral blood mononuclear cells from people with chronic myeloid leukemia treated with ponatinib.
Front Pharmacol
September 2024
Immunopathology and Viral Reservoir Unit, National Center of Microbiology, Instituto de Salud Carlos III, Madrid, Spain.
Article Synopsis
- - HIV-1 infection persists due to long-term viral reservoirs in latently infected CD4 T cells, prompting the need for strategies to stimulate cytotoxic immunity, including the "Shock and Kill" approach.
- - Ponatinib, a tyrosine kinase inhibitor used for chronic myeloid leukemia, has shown effectiveness against HIV-1 and may enhance the immune response against both cancer and viral infections.
- - In a study of patients with chronic myeloid leukemia who switched from imatinib to ponatinib, results indicated that ponatinib treatment significantly reduced HIV-1 infection rates and increased the cytotoxic response from peripheral blood mononuclear cells, with effects lasting at least 12 months post-treatment.
Genetic diversity in the partial sequence of the HIV-1 gag gene among people living with multidrug-resistant HIV-1 infection.
Rev Inst Med Trop Sao Paulo
June 2024
Fundação Pró-Sangue Hemocentro de São Paulo, São Paulo, São Paulo, Brazil.
The group-specific antigen (gag) plays a crucial role in the assembly, release, and maturation of HIV. This study aimed to analyze the partial sequence of the HIV gag gene to classify HIV subtypes, identify recombination sites, and detect protease inhibitor (PI) resistance-associated mutations (RAMs). The cohort included 100 people living with HIV (PLH) who had experienced antiretroviral treatment failure with reverse transcriptase/protease inhibitors.
View Article and Find Full Text PDFIncreasing intra- and inter-subtype HIV diversity despite declining HIV incidence in Uganda.
medRxiv
March 2024
Department of Pathology, Johns Hopkins School of Medicine, Baltimore, MD, USA.
HIV incidence has been declining in Africa with scale-up of HIV interventions. However, there is limited data on HIV evolutionary trends in African populations with waning epidemics. We evaluated changes in HIV viral diversity and genetic divergence in southern Uganda over a twenty-five-year period spanning the introduction and scale-up of HIV prevention and treatment programs using HIV sequence and survey data from the Rakai Community Cohort Study, an open longitudinal population-based HIV surveillance cohort.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!